Download PDF
Thromb Haemost 2017; 117(11): 2186-2193
DOI: 10.1160/TH17-04-0237
Atherosclerosis and Ischaemic Disease
Schattauer GmbH Stuttgart

The Performance of CRUSADE and ACUITY Bleeding Risk Scores in Ticagrelor-Treated ACS Patients Who Underwent PCI

Shaozhi Xi   *
,
Shanshan Zhou   *
,
Xuyun Wang
,
Jia Liu
,
Liuan Qin
,
Jun Liu
,
Tong Yin
,
Yundai Chen
Further Information

Publication History

05 April 2017

18 July 2017

Publication Date:
30 November 2017 (online)

Also available at
    Permissions and Reprints

Abstract

The performance of the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines) and ACUITY (Acute Catheterization and Urgent Intervention Triage strategy) risk scores for the prediction of major bleeding in ticagrelor-treated acute coronary syndrome (ACS) patients who underwent percutaneous coronary intervention (PCI) is unknown. The aim of the present study is to validate the performance of both scores in a contemporary Chinese cohort of ACS patients hospitalized for PCI and administrated with ticagrelor. From January 2013 to December 2014, a total of 629 ticagrelor-treated ACS patients who underwent PCI were recruited consecutively. The overall rate of major bleeding defined by the BARC (Bleeding Academic Research Consortium) criteria was 1.7%. This incidence increased with the risk category of both the CRUSADE (very low, 0.6%; low, 1.3%; moderate, 1.1%; high, 7.0%; and very high, 13.0%; p = 0.001) and the ACUITY score (low, 0.6%; moderate, 1.4%; high, 4.9%; and very high, 7.0%; p = 0.003). The CRUSADE score demonstrated adequate calibration and discriminatory capacity for the patients as a whole (HL-p [Hosmer–Lemeshow goodness-of-fit test p-value] >0.3; AUC [area under the curve]: 0.78), with the excellent performance in the subgroups of acute myocardial infarction, men, diabetes and those implanted with more than two DESs (AUC: 0.85, 0.80, 0.93 and 0.93, respectively). For the ACUITY score, adequate calibration and discriminatory capacity could be observed for the whole patients (HL-p > 0.3; AUC: 0.78), with excellent performance for the patients with diabetes or those implanted with more than two DESs (AUC: 0.90 and 0.97, respectively). In conclusion, both CRUSADE and ACUITY risk scores performed adequate discriminatory power for the prediction of major bleeding within 30 days in ticagrelor-treated ACS patients who underwent PCI.

Keywords

ticagrelor - major bleeding - CRUSADE risk score - ACUITY risk score - acute coronary syndrome

* Shaozhi Xi and Shanshan Zhou as co-first authors contribute equally to the manuscript.


 

  • References

  • 1 Storey RF, Husted S, Harrington RA. , et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol 2007; 50 (19) 1852-1856
    CrossrefPubMedGoogle Scholar
  • 2 Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J 2006; 27 (09) 1038-1047
    CrossrefPubMedGoogle Scholar
  • 3 Windecker S, Kolh P, Alfonso F. , et al; Authors/Task Force members. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014; 35 (37) 2541-2619
    CrossrefPubMedGoogle Scholar
  • 4 Levine GN, Bates ER, Bittl JA. , et al. 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2016; 68 (10) 1082-1115
    CrossrefPubMedGoogle Scholar
  • 5 Roffi M, Patrono C, Collet JP. , et al; Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016; 37 (03) 267-315
    CrossrefPubMedGoogle Scholar
  • 6 Section of Interventional Cardiology of Chinese Society of Cardiology of Chinese Medical Association; Specialty Committee on Prevention and Treatment of Thrombosis of Chinese College of Cardiovascular Physicians; Editorial Board of Chinese Journal of Cardiology. Chinese guideline for percutaneous coronary intervention (2016) [in Chinese]. Zhonghua Xin Xue Guan Bing Za Zhi 2016; 44 (05) 382-400
    PubMedGoogle Scholar
  • 7 Wiviott SD, Braunwald E, McCabe CH. , et al; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007; 357 (20) 2001-2015
    CrossrefPubMedGoogle Scholar
  • 8 Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KA, Yusuf S. Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. Circulation 2006; 114 (08) 774-782
    CrossrefPubMedGoogle Scholar
  • 9 Wallentin L, Becker RC, Budaj A. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009; 361 (11) 1045-1057
    CrossrefPubMedGoogle Scholar
  • 10 Husted S, James S, Becker RC. , et al; PLATO study group. Ticagrelor versus clopidogrel in elderly patients with acute coronary syndromes: a substudy from the prospective randomized PLATelet inhibition and patient Outcomes (PLATO) trial. Circ Cardiovasc Qual Outcomes 2012; 5 (05) 680-688
    CrossrefPubMedGoogle Scholar
  • 11 Kang HJ, Clare RM, Gao R. , et al; PLATO Investigators. Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: a retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Am Heart J 2015; 169 (06) 899-905.e1
    CrossrefPubMedGoogle Scholar
  • 12 Alexopoulos D, Xanthopoulou I, Deftereos S. , et al. Contemporary antiplatelet treatment in acute coronary syndrome patients undergoing percutaneous coronary intervention: 1-year outcomes from the GReek AntiPlatElet (GRAPE) Registry. J Thromb Haemost 2016; 14 (06) 1146-1154
    CrossrefPubMedGoogle Scholar
  • 13 Généreux P, Giustino G, Witzenbichler B. , et al. Incidence, predictors, and impact of post-discharge bleeding after percutaneous coronary intervention. J Am Coll Cardiol 2015; 66 (09) 1036-1045
    CrossrefPubMedGoogle Scholar
  • 14 Antman EM, Cohen M, Bernink PJ. , et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000; 284 (07) 835-842
    CrossrefPubMedGoogle Scholar
  • 15 Subherwal S, Bach RG, Chen AY. , et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: the CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA Guidelines) Bleeding Score. Circulation 2009; 119 (14) 1873-1882
    CrossrefPubMedGoogle Scholar
  • 16 Mehran R, Pocock SJ, Nikolsky E. , et al. A risk score to predict bleeding in patients with acute coronary syndromes. J Am Coll Cardiol 2010; 55 (23) 2556-2566
    CrossrefPubMedGoogle Scholar
  • 17 Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (01) 31-41
    CrossrefPubMedGoogle Scholar
  • 18 Thygesen K, Alpert JS, White HD. ; Joint ESC/ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction. Universal definition of myocardial infarction. Eur Heart J 2007; 28 (20) 2525-2538
    CrossrefPubMedGoogle Scholar
  • 19 Mehran R, Rao SV, Bhatt DL. , et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
    CrossrefPubMedGoogle Scholar
  • 20 Lemeshow S, Hosmer Jr DW. A review of goodness of fit statistics for use in the development of logistic regression models. Am J Epidemiol 1982; 115 (01) 92-106
    CrossrefPubMedGoogle Scholar
  • 21 Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982; 143 (01) 29-36
    CrossrefPubMedGoogle Scholar
  • 22 Abu-Assi E, Gracía-Acuña JM, Ferreira-González I, Peña-Gil C, Gayoso-Diz P, González-Juanatey JR. Evaluating the Performance of the Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the ACC/AHA Guidelines (CRUSADE) bleeding score in a contemporary Spanish cohort of patients with non-ST-segment elevation acute myocardial infarction. Circulation 2010; 121 (22) 2419-2426
    CrossrefPubMedGoogle Scholar
  • 23 Ariza-Solé A, Sánchez-Elvira G, Sánchez-Salado JC. , et al. CRUSADE bleeding risk score validation for ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Thromb Res 2013; 132 (06) 652-658
    CrossrefPubMedGoogle Scholar
  • 24 Abu-Assi E, Raposeiras-Roubin S, Lear P. , et al. Comparing the predictive validity of three contemporary bleeding risk scores in acute coronary syndrome. Eur Heart J Acute Cardiovasc Care 2012; 1 (03) 222-231
    CrossrefPubMedGoogle Scholar
  • 25 Flores-Ríos X, Couto-Mallón D, Rodríguez-Garrido J. , et al. Comparison of the performance of the CRUSADE, ACUITY-HORIZONS, and ACTION bleeding risk scores in STEMI undergoing primary PCI: insights from a cohort of 1391 patients. Eur Heart J Acute Cardiovasc Care 2013; 2 (01) 19-26
    CrossrefPubMedGoogle Scholar
  • 26 Jinatongthai P, Khaisombut N, Likittanasombat K, Chaiyakunapruk N, Watcharathanakij S, Nathisuwan S. Use of the CRUSADE bleeding risk score in the prediction of major bleeding for patients with acute coronary syndrome receiving enoxaparin in Thailand. Heart Lung Circ 2014; 23 (11) 1051-1058
    CrossrefPubMedGoogle Scholar
  • 27 Kharchenko MS, Erlikh AD, Gratsianskiĭ NA. Assessment of the prognostic value of the CRUSADE score in patients with acute coronary syndromes hospitalized in a noninvasive hospital [in Russian]. Kardiologiia 2012; 52 (08) 27-32
    PubMedGoogle Scholar
  • 28 Taha S, D'Ascenzo F, Moretti C. , et al. Accuracy of bleeding scores for patients presenting with myocardial infarction: a meta-analysis of 9 studies and 13 759 patients. Postepy Kardiol Interwencyjnej 2015; 11 (03) 182-190
    PubMedGoogle Scholar
  • 29 Correia LC, Ferreira F, Kalil F. , et al. Comparison of ACUITY and CRUSADE Scores in Predicting Major Bleeding during Acute Coronary Syndrome. Arq Bras Cardiol 2015; 105 (01) 20-27
    PubMedGoogle Scholar
  • 30 O'Donoghue ML, Vaidya A, Afsal R. , et al. An invasive or conservative strategy in patients with diabetes mellitus and non-ST-segment elevation acute coronary syndromes: a collaborative meta-analysis of randomized trials. J Am Coll Cardiol 2012; 60 (02) 106-111
    CrossrefPubMedGoogle Scholar
  • 31 Manoukian SV, Feit F, Mehran R. , et al. Impact of major bleeding on 30-day mortality and clinical outcomes in patients with acute coronary syndromes: an analysis from the ACUITY Trial. J Am Coll Cardiol 2007; 49 (12) 1362-1368
    CrossrefPubMedGoogle Scholar
  • 32 Baber U, Dangas G, Chandrasekhar J. , et al. Time-dependent associations between actionable bleeding, coronary thrombotic events, and mortality following percutaneous coronary intervention: results from the PARIS registry. JACC Cardiovasc Interv 2016; 9 (13) 1349-1357
    PubMedGoogle Scholar
  • 33 Moscucci M, Fox KA, Cannon CP. , et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24 (20) 1815-1823
    CrossrefPubMedGoogle Scholar
  • 34 Loh JP, Pendyala LK, Torguson R. , et al. Incidence and correlates of major bleeding after percutaneous coronary intervention across different clinical presentations. Am Heart J 2014; 168 (03) 248-255
    CrossrefPubMedGoogle Scholar